Gildeuretinol acetate administration demonstrated a statistically significant reduction in the growth rate of retinal atrophic lesions in Stargardt disease (STGD), with a 21.6% relative reduction over 24 months compared to untreated cases.
The TEASE-1 trial confirmed an acceptable safety profile for oral gildeuretinol acetate, with adverse events primarily mild or moderate and no treatment-related serious adverse events.
Integrating data from randomized and natural history cohorts offers a robust understanding of STGD lesion progression and therapeutic impact.
Further research is needed to clarify the clinical significance of lesion growth reduction and to explore long-term functional outcomes.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
